



## REVIEW ARTICLE

# Low FODMAPs diet for functional abdominal pain disorders in children: critical review of current knowledge ☆,☆☆



Licia Pensabene <sup>a,\*</sup>, Silvia Salvatore <sup>b</sup>, Rossella Turco <sup>c</sup>, Flora Tarsitano <sup>a</sup>, Daniela Concolino <sup>a</sup>, Maria Elisabetta Baldassarre <sup>d</sup>, Osvaldo Borrelli <sup>e</sup>, Nikhil Thapar <sup>e</sup>, Yvan Vandenplas <sup>f</sup>, Annamaria Staiano <sup>c</sup>, Miguel Saps <sup>g</sup>

<sup>a</sup> University "Magna Graecia" of Catanzaro, Pediatric Unit, Department of Medical and Surgical Sciences, Catanzaro, Italy

<sup>b</sup> University of Insubria, Section of Pediatrics, Department of Medicine and Surgery, Varese, Italy

<sup>c</sup> University of Naples "Federico II", Section of Pediatrics, Department of Translational Medical Science, Naples, Italy

<sup>d</sup> Aldo Moro University of Bari, Department of Biomedical Science and Human Oncology, Bari, Italy

<sup>e</sup> Great Ormond Street Hospital for Children, Neurogastroenterology and Motility Unit, Department of Gastroenterology, London, United Kingdom

<sup>f</sup> Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, KidZ Health Castle, Brussels, Belgium

<sup>g</sup> University of Miami, Holtz Children's Hospital, Miller School of Medicine, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Miami, United States

Received 1 March 2019; accepted 13 March 2019

Available online 24 April 2019

### KEYWORDS

Functional abdominal pain disorders;  
Fermentable oligosaccharides;  
Disaccharides;  
Monosaccharides;  
Polyol diet;  
Children

### Abstract

**Objective:** This narrative review aimed to provide practitioners a synthesis of the current knowledge on the role of a low Fermentable Oligosaccharides Disaccharides Monosaccharides and Polyols diet in reducing symptoms associated with functional abdominal pain disorders in children. This review is focused on the pathophysiology, efficacy and criticism of low Fermentable Oligosaccharides Disaccharides Monosaccharides and Polyols diet in children.

**Sources:** Cochrane Database, Pubmed and Embase were searched using specific terms for Fermentable Oligosaccharides Disaccharides Monosaccharides and Polyols diet interventions and functional abdominal pain disorders.

☆ Please cite this article as: Pensabene L, Salvatore S, Turco R, Tarsitano F, Concolino D, Baldassarre ME, et al. Low FODMAPs diet for functional abdominal pain disorders in children: critical review of current knowledge. J Pediatr (Rio J). 2019;95:642–56.

☆☆ Study conducted at University Magna Graecia of Catanzaro, Department of Medical and Surgical Sciences, Catanzaro, Italy.

\* Corresponding author.

E-mail: [pensabene@unicz.it](mailto:pensabene@unicz.it) (L. Pensabene).

**PALAVRAS-CHAVE**

Distúrbios de dor abdominal funcional; Oligossacarídeos fermentáveis; Dissacarídeos; Monossacarídeos; Dieta de polióis; Crianças

**Summary of the findings:** In children, only one Randomized Control Trial and one open-label study reported positive results of low Fermentable Oligosaccharides Disaccharides Monosaccharides and Polyols diet; one Randomized Control Trial showed exacerbation of symptoms with fructans in children with Irritable Bowel Syndrome; no effect was found for the lactose-free diet whilst fructose-restricted diets were effective in 5/6 studies.

**Conclusions:** In children there are few trials evaluating low Fermentable Oligosaccharides Disaccharides Monosaccharides and Polyols in functional abdominal pain disorders, with encouraging data on the therapeutic efficacy particularly of fructose-restricted diet. Additional efforts are still needed to fill this research gap and clarify the most efficient way for tailoring dietary restrictions based on the patient's tolerance and/or identification of potential biomarkers of low Fermentable Oligosaccharides Disaccharides Monosaccharides and Polyols efficacy, to maintain nutritional adequacy and to simplify the adherence to diet by labeling Fermentable Oligosaccharides Disaccharides Monosaccharides and Polyols content in commercial products.

© 2019 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

### Dieta com baixo teor de FODMAPs para distúrbios de dor abdominal funcional em crianças: revisão crítica do conhecimento atual

#### Resumo

**Objetivo:** Nos últimos anos, foram feitos esforços consideráveis para esclarecer o papel da dieta com baixo teor de oligossacarídeos fermentáveis, dissacarídeos, monossacarídeos e polióis (FODMAPs) para o tratamento de distúrbios gastrointestinais funcionais (DGIFs). Esta revisão narrativa teve como objetivo fornecer aos profissionais uma síntese do conhecimento atual sobre o papel de uma dieta com baixo teor de FODMAPs (BFM) na redução dos sintomas associados a distúrbios funcionais de dor abdominal (DFDA) em crianças. Esta revisão está focada na fisiopatologia, eficácia e crítica da dieta BFM em crianças.

**Fontes:** O banco de dados Cochrane, Pubmed e Embase foram pesquisados com o uso dos termos específicos para intervenções na dieta FODMAP e DFDA.

**Resumo dos achados:** Em crianças, apenas um estudo controlado randomizado e um estudo aberto relataram resultados positivos da dieta BFM; um estudo controlado randomizado mostrou exacerbção dos sintomas com frutanos em crianças com síndrome do intestino irritável nenhum efeito foi encontrado para a dieta livre de lactose, enquanto dietas com restrição de frutose foram eficazes em 5/6 estudos.

**Conclusões:** Existem poucos estudos que avaliam BFM em DFDA em crianças, com dados encorajadores sobre a eficácia terapêutica, particularmente de dietas com restrição de frutose. Esforços adicionais ainda são necessários para preencher essa lacuna de pesquisa e esclarecer a maneira mais eficiente de adaptar as restrições dietéticas com base na tolerância do paciente e/ou identificação de biomarcadores potenciais de eficácia da BFM, para manter a adequação nutricional e simplificar a adesão à dieta, ao incluir informações sobre conteúdo de FODMAPs em rótulos de produtos comerciais.

© 2019 Sociedade Brasileira de Pediatria. Publicado por Elsevier Editora Ltda. Este é um artigo Open Access sob uma licença CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

The role of diet is increasingly emerging in different gastrointestinal disorders such as functional gastrointestinal (GI) disorders (FGIDs), irritable bowel syndrome (IBS), constipation, diverticular disease, and inflammatory bowel disease.<sup>1</sup> FGIDs are common disorders characterized by chronic or recurrent GI symptoms not explained by biochemical or structural abnormalities.<sup>2</sup> The pathogenesis of FGIDs remains poorly understood, although a complex altered interaction between gut and brain has been recently advocated.<sup>3</sup> In the absence of specific biomarkers, FGIDs

are clinically classified according to the Rome IV diagnostic criteria, mainly based on a thorough patient history.<sup>4,5</sup> In children, FGIDs may be classified in three main categories: disorders of nausea and vomiting, disorders of defecation or pain-based (such as functional abdominal pain disorders [FAPDs]). FAPDs comprise four distinct disorders: IBS, functional dyspepsia, abdominal migraine, and FAP-not otherwise specified (FAP-NOS), meaning that the FAP does not fit the specific diagnostic pattern of one of the first three disorders.<sup>6</sup> Functional dyspepsia and IBS frequently occur both in children and adults. The prevalence of IBS ranges from 10 to 25% of adults<sup>7</sup> and 0

to 45% of children, respectively.<sup>8,9</sup> IBS strongly impairs quality of life, social functioning, school attendance, and work productivity; it also substantially increases health care costs. In the pathogenesis of FGIDs different mechanisms have been proposed: increased pain sensitivity or visceral hypersensitivity,<sup>10,11</sup> abnormal gut motility,<sup>12</sup> small intestinal bacterial overgrowth,<sup>13</sup> low-grade intestinal inflammation,<sup>14</sup> infections,<sup>15–17</sup> psychosocial factors,<sup>18</sup> early-life events,<sup>19,20</sup> cow's milk protein allergy,<sup>21,22</sup> and dysregulated gut–brain axis.<sup>23,24</sup> Familiar aggregation of FGIDs is commonly found and may be secondary to social learning and genetic factors.<sup>25</sup> Gene variants coding for disaccharidases with defective or reduced enzymatic activity has been recently found to predispose to IBS in a subset of adult patients.<sup>26</sup> The gut microbiome is also recognized as a key player in FGID and intestinal dysbiosis has been reported in patients with IBS compared to healthy subjects.<sup>27</sup> This microbial diversity could lead to enhanced intestinal permeability, mucosal immune activation, altered gut motility, and visceral hypersensitivity.<sup>27</sup> The concept of a strict relation between microbiota and immunity, motility, nervous system, stress, and behavior has resulted in the joined term of microbiome–gut–brain axis. This axis has emerged as responsible for the control and regulation of different GI and neurological functions.<sup>28</sup> In this context, the importance of early adverse events and diet has long been recognized. The perinatal period with its pivotal influence in the maturation of both gut and brain is a critical period in which different determinants may predispose to the development of FGIDs.<sup>27</sup>

Most patients with FGIDs report that their GI symptoms are generically or specifically related to food, although evidence of this relation is often difficult to prove, particularly in children.<sup>29–31</sup> Multiple interacting and confounding mechanisms may be involved in the patient's perceived "food intolerance." In IBS patients, postprandial symptoms can be triggered by overfeeding, hyperactive gastrocolonic response, visceral sensitivity,<sup>32,33</sup> dysbiosis, disordered gut–brain signaling,<sup>34</sup> anticipation, allergies, and malabsorption. In the absence of readily available, easy to administer, reliable office-based tests, empirical dietary restrictions are often indicated in the absence of proven intolerance, malabsorption, or a confirmed diagnosis of food allergies.<sup>35</sup> This is relevant, as changes in diet can interfere with the individual metabolism, intestinal motility, secretions, sensitivity, barrier function, gut microbiota,<sup>36</sup> and adequate nutrition. As expected, given the heterogeneity of FGIDs, individual patients, and underlying factors, no single treatment has shown to be effective in all patients. Unnecessary diet restrictions are of particular concern in growing children. Therefore, it is of great importance to have a deep understanding of the evidence behind each dietary recommendation given to children, in order to design personalized treatment plans.

In the last years, great interest has been focused on dietary fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) for the treatment of FGIDs in adults and children. The low FODMAPs (LFM) diet restricts the intake of several fermentable carbohydrates, including foods containing fructans (wheat and onion), galacto-oligosaccharides (legumes and cabbage),

lactose (dairy products), fructose in excess of glucose (pears and apples), and sugar polyols, such as sorbitol and mannitol (stone fruits and artificial sweeteners).<sup>18</sup> Promising effect of the low FODMAP diet in reducing functional GI symptoms in adult patients has been shown,<sup>37</sup> but there is limited evidence in children.<sup>38</sup>


This narrative review explores the available literature on LFM diets and aims to provide practitioners with a critical synthesis of the pathophysiology, mechanism of action, efficacy, and limits to help in identifying a diet-tailored intervention for FAPDs in children.

## Methods

A literature search of MEDLINE (*via* PubMed), Embase, and the Cochrane Library databases was conducted, from inception to August 2018, focusing on LFM diet in relation with FAPDs. The following terms were queried: "FODMAP," "FODMAPs," "fermentable oligosaccharides, disaccharides, monosaccharides, and polyols," "fermentable, poorly absorbed, short chain carbohydrates," "lactose-free diet," "fructose," "fructans," "sorbitol" AND "functional gastrointestinal disorders," OR "functional abdominal pain," "recurrent abdominal pain," "irritable bowel syndrome," "IBS." The authors restricted the search to English language and children (aged 0–18 years). Because the purpose of this review was not to duplicate a recent systematic review on FODMAPs but rather to critically review the available literature and provide the clinicians a practical summary of LFD in children, the search was expanded to include prospective and retrospective studies, randomized controlled trials (RCTs), reviews, and editorials.

## FODMAPs

Throughout the 1980s and 1990s, clinical studies focused primarily on the role of lactose, fructose, and sorbitol intake as triggers of GI symptoms including abdominal pain, discomfort, bloating, distension, and diarrhea. In recent years, the focus has shifted to fructo-oligosaccharides (FOS) (fructans) and galacto-oligosaccharides (GOS) ingestion as possible culprits of IBS.<sup>39</sup> Grouping all these fermentable short-chain carbohydrates and sugar alcohols together led to the acronym FODMAPs. Poor absorption, osmotic activity, and rapid fermentation by the luminal microbiome<sup>40</sup> may result in excessive gas production,<sup>41</sup> luminal distension, loose stools, and visceral hypersensitivity, features that are consistent with IBS. Moreover, small intestinal bacterial overgrowth that may occur in some patients with IBS can increase the metabolism of these carbohydrates and consequent gas production.<sup>39</sup> Symptoms related to FODMAPs may also derive from changes in the gut microbiota and metabolism, endocrine cells, immune function, and intestinal barrier.<sup>42–45</sup> Intriguingly, a non-restrictive FODMAP diet may be both associated with loose stools and with delayed gut transit time and constipation, as occurs in individuals with methane-producing microbiota.<sup>46,47</sup> Furthermore, dietary intake of carbohydrate-related prebiotics (fibers) interacting with intestinal probiotics may have beneficial effects on human health<sup>48,49</sup> (Fig. 1).



**Figure 1** Mechanism of action of carbohydrate-related prebiotics + probiotics and their effects on human health. Modified from: Nath et al.<sup>48</sup> and Markowiak et al.<sup>49</sup>

The LFM diet was first developed in 1999 by Dr. Gibson and Dr. Shepard at Monash University in Melbourne. In 2005, the same authors proposed that a diet high in FODMAPs might perpetuate (functional) gastrointestinal symptoms in patients with Crohn's disease.<sup>50</sup> This concept was soon extrapolated to IBS patients. Early studies showed the positive effects of fructose and short-chain fructans restriction in adults with fructose malabsorption. Moreover, the co-ingestion of fructose and glucose counteracts the detrimental effect of the excess of free fructose in the small intestine of IBS patients with fructose malabsorption due to facilitated combined transport.<sup>51</sup> Since then, multiple trials have been conducted and LFM is currently considered an effective dietary approach in adults with IBS,<sup>39</sup> particularly when symptoms persist despite lifestyle changes and other dietary advice.<sup>52</sup> FODMAPs are present in foods containing wheat, rye, barley, legumes, lentils, chickpeas, Brussels sprouts, asparagus, artichokes, beets, broccoli, cabbage, fennel, onions, garlic, leeks, okra, peas, shallots, apples, peaches, persimmon, watermelon, and pistachios.<sup>53</sup> A list of food with low FODMAP content is shown in Table 1.<sup>54–59</sup>

A study in ileostomates clarified that the fermentable load and volume of liquid delivered to the large intestine are increased by FODMAPs.<sup>40</sup> The gut microbiota rapidly ferment carbohydrates, resulting in luminal distension and abdominal pain in adults with visceral hypersensitivity. A scintigraphic study demonstrated that fructose-sorbitol ingestion reduced the oro-cecal transit time by approximately 3 h in healthy individuals.<sup>60</sup> Other studies showed that FODMAPs can change the microbiota composition, decrease urinary histamine,<sup>61</sup> and increase pro-inflammatory cytokines<sup>62</sup> and visceral nociception.<sup>63</sup> A diet high in FODMAPs (HFM) increased rat fecal Gram-negative bacteria, elevated lipopolysaccharides, and induced intestinal barrier dysfunction and visceral

hypersensitivity.<sup>63</sup> A four-week LFM diet was able to reverse these manifestations, improving IBS symptoms and reducing fecal lipopolysaccharides levels. Intracolonic administration of fecal supernatant from IBS patients to rats caused visceral hypersensitivity in the animals, which was not transferred if the patients were on an LFM diet.<sup>63</sup>

### The LFM diet: practical steps

A LFM diet can be implemented following two different approaches: bottom-up and top-down.<sup>64</sup> The bottom-up approach is a progressive gradual elimination of single products (or groups of products) from the diet until the symptoms are alleviated and allows specifying the patient's limit of tolerance for FODMAPs. This method is preferred in patients: (1) who have not yet been diagnosed with IBS but experience suggestive symptoms affecting their quality of life; (2) who are already on other elimination diet; or (3) who struggle to follow a full LFM.<sup>65</sup> The second approach, top-down, more commonly used in experimental studies, require transient reduction or elimination of all foods high in FODMAPs from the diet, being therefore far more restrictive. Next, products containing FODMAPs are gradually reintroduced into the diet.<sup>65,66</sup>

In an LFM diet, there are three distinct phases: elimination, determination of sensitivities, and personalization.<sup>36,67,68</sup> The majority of the studies conducted on the LFM diet have focused on the elimination phase, usually prescribed for two to six weeks, followed by assessment of symptom improvement. After completing the first phase of FODMAP restriction, if a therapeutic response is achieved, patients should undergo a structured reintroduction phase (ideally with the help of a dietitian) to determine the type and amount of FODMAPs that can

**Table 1** List of foods with low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) content.

Nutrients	Low FODMAP content
Cereals	Gluten free products, rice, corn pasta, tortilla chips, quinoa, oats, polenta, sourdough, noodles
Milk products	Lactose free products, rice milk, soy milk, sorbets
Cheese	Hard cheeses, Cheddar, Parmesan, mozzarella, Swiss, firm tofu, tempeh, Brie, Camembert
Fruits	Bananas, cantaloupe, carambola, durian, honeydew melon, kiwi, orange, passion fruit, pawpaw, all berries (raspberries, blueberries, cranberries, strawberries) except than blackberries, tangelo, grapes, grapefruit, all nuts (except cashew and pistachios, and less than ten), almonds (less than 10), macadamia, olives, pumpkin seeds, flax and chia seeds, coconut, lemon, limes, papaya, rhubarb
Vegetables	Bamboo shoot, bok choy, capsicum, celery, chives, choko, choy sum, corn, eggplant, green bean, bean sprouts, lettuce, parsnip, pumpkin, silverbeet, tomato, potatoes, spring onion (green part only), garlic-infused oil, bell peppers, Swiss chard, carrots, spinach, zucchini, beet root (no more than four slices), broccoli (no more than 1/2 cup)
Legumes	Canned pumpkin, canned chickpeas, canned lentils
Sweeteners	Honeydew, golden syrup, maple syrup, glucose, sucrose (table sugar), aspartame, stevia, molasses, any sweeteners not containing fructose and not ending in ‘-ol’
References	Khan et al., 2015 <sup>54</sup> ; Barrett, 2017 <sup>55</sup> ; Varney et al., 2017 <sup>56</sup> ; Monash University Low FODMAP Diet App., 2016 <sup>57</sup> ; Canadian Digestive Health Foundation, 2019 <sup>58</sup> ; Magge and Lembo, 2012 <sup>59</sup>

Note: FODMAP composition is affected by food processing techniques. Processes that involve heating and water can reduce the content of water soluble FODMAPs (such as fructans and GOS) leaching into the surrounding liquid (canned legumes are lower in FODMAP, GOS, than boiled legumes). Servings should also be considered because an excessive intake may increase the content of FODMAP diet (*i.e.*, almonds and other nuts, if less than ten pieces, are low in FODMAP; large bananas have increased FODMAP).<sup>a</sup> Gluten free products are low-FODMAP except if they contain honey or fructose, or polyol sweeteners.

be tolerated before experiencing symptoms, thus creating a personalized LFM diet.<sup>67</sup> With this approach, based on tailored dietary restrictions demonstrated by the patient's tolerance, nutritional adequacy is more likely to be maintained and alterations of the luminal microbiota may be partially offset.<sup>69</sup>

FODMAP content guidance is available *via* scientific and lay publications for many types of foods<sup>70</sup>; the majority of information and analysis originated in Australia.<sup>71</sup> The discordance of FODMAP content in other countries food lists could be partly related to the lack of clear FODMAP content guidance in different geographical areas.<sup>72</sup> Chumpitazi et al.<sup>70</sup> found an excessive FODMAP content in several processed foods, previously considered as LFM foods, such as gluten-free baked products and manufactured beverages. Also, in Australian manufactured gluten-free bread, the fructose content is sometimes higher than the nongluten-free counterparts.<sup>73</sup> Appropriate assessment of FODMAPs and fructose and/or fructans may be helpful for patients with different tolerance to different carbohydrate.<sup>74</sup> The development of technologies enabling the reduction of FODMAPs in processed food is also recommended.<sup>64</sup>

### Criticisms of the low FODMAP diet

Despite the demonstrated effectiveness of the LFM diet in a subset of patients with IBS, multiple concerns have been raised.<sup>64,75</sup> Those include: (1) the lack of high-quality, randomized, placebo-controlled trials in children<sup>76–78</sup>; (2) the complexity and difficulty of teaching the diet; (3) the lack of specific cut-off levels for FODMAP content; (4) the paucity of data on safety and long-term efficacy; and (5) its effect on the gut microbiota.<sup>79</sup>

In addition to the impact on nutrient intake, the LFM diet may have psychosocial impacts. Patients have reported finding the diet ‘too demanding to follow’,<sup>80</sup> and a questionnaire study reported difficulty in eating out and traveling for those following a long-term FODMAP diet.<sup>81</sup>

However, the beneficial effects of the LFM diet on quality of life have been demonstrated.<sup>82,83</sup> Despite the perceived complexity of following such a restrictive diet,<sup>83</sup> 57% of patients reported adequate relief of symptoms. Of 90 patients enrolled in a prospective observational study, 60% stated that the LFM diet was easy to follow.<sup>84</sup>

In terms of safety, major concerns regard possible nutrient deficiencies, particularly during the initial elimination phase of high FODMAP containing foods.<sup>79</sup> Reduced intake of grains, fruits, vegetables, and dairy products can restrict dietary choices, and may result, especially in growing children, in weight loss, failure to thrive, risk of fiber and micronutrient deficiencies (mainly iron, calcium, retinol, thiamin, and riboflavin),<sup>83,85–87</sup> and eating disorders such as poor eating habits and food aversions. In the largest RCT on LFM diets<sup>79</sup> the energy intake was not different to those following normal diet, and the change in body weight was minimal (mean < 0.5 kg) and not different between both groups.<sup>83,85</sup> Conversely, two other 4-week RCTs reported reduction in energy intake in the LFM group.<sup>44,86,87</sup> Moreover, some FODMAP-rich vegetables (*e.g.*, cauliflower, onion, garlic) contain natural antioxidants, such as flavonoids, carotenoids, and vitamin C; some fruits and blackberries contain phenolic acid and anthocyanins, and wheat is a major source of phenolic acids.<sup>88,89</sup> However, a recent follow-up study demonstrated no nutritional inadequacies following the reintroduction period in IBS patients on an ‘adapted FODMAP’ diet.<sup>69</sup> Additionally,

the only two long-term studies in patients with IBS following a personalized FODMAP diet with FODMAP reintroduction according to patients' tolerance, found that calcium,<sup>81,82</sup> iron, and other micronutrients<sup>81</sup> were not compromised at 6–18 months.

Two RCTs in adults with IBS<sup>29,86</sup> and a small, uncontrolled trial in patients with radiation-induced gastrointestinal symptoms<sup>80</sup> reported reductions in fiber intake during the LFM diet compared with baseline. Inadequate substitution of high FODMAP grains and fruit and vegetables with suitable LFM/high-fiber replacements could explain these findings. Moreover another large RCT found no difference in fiber or macronutrient intake after a four-week LFM diet in IBS.<sup>85</sup> The nutritional impact may vary mostly due to the availability of alternative food choices, and the completeness of dietary advice given.

About the influence of diet on the gut microbiome, species considered beneficial for host health, such as *bifidobacteria* and *Faecalibacterium prausnitzii*, were reduced in IBS patients receiving a LFM diet, most likely as a consequence of reducing prebiotic intake.<sup>34</sup> The abundance of several bacteria (*F. prausnitzii*, *Actinobacteria*, and *Bifidobacterium*) rebounded after ten days of FOS supplementation<sup>62</sup> and the strain diversity did not decrease with FODMAP restriction in four studies.<sup>61,87,90,91</sup> Moreover, Staudacher et al.<sup>83</sup> found that the reduction in *Bifidobacterium* induced by a LFM diet was counteracted through a specific probiotic preparation containing *bifidobacteria*.

### Evidence for using LFM diets to manage gastrointestinal symptoms in adults

A recent systematic review<sup>38</sup> has found that in 12 out of 13 trials in adults, a FODMAPs-restricted diet was an effective dietary intervention for reducing IBS symptoms. However, a recent RCT has shown that although the LFM diet reduced symptoms of IBS, it was no better than traditional dietary advice.<sup>44</sup> Another trial found that the proportion of subjects reporting adequate relief of IBS-D symptoms by  $\geq 50\%$  (primary end point) during weeks three and four did not significantly differ from those not receiving an LFM diet.<sup>87</sup>

In athletes with a self-reported history of persistent exercise associated GI distress, a short-term LFM resulted in lower daily GI symptoms compared with a high FODMAP diet.<sup>92</sup>

### Evidence for using LFM diets to manage FAPDs in children

The pediatric literature search retrieved 156 records and, according to the selected inclusion criteria, 24 records were included in this review (Fig. S1).

### Evidence for comprehensive LFM diet in children with FAPDs

The summary of the studies in children is shown in Table 2.

In an open-label study,<sup>93</sup> conducted in a small sample of eight children with IBS, abdominal pain severity,

intensity, and interference with daily activities were significantly reduced after one week of LFM diet. Four out of eight children had  $\geq 50\%$  decrease in abdominal pain frequency as compared to the baseline.<sup>93</sup> In a randomized double-blind crossover trial,<sup>90</sup> 33 children with IBS were randomized to receive a LFM diet (0.15 g/kg/day, maximum 9 g/day of FODMAPs) or a typical American childhood diet (TACD) containing 0.7 g/kg/day (maximum 50 g/day) of FODMAPs for 48 h. After a five-day washout period, the children were "crossed over" to the other diet for another 48 h. Children on LFM diet reported significantly lower number of daily episodes of abdominal pain compared to children following TACD. Children who had significant improvement on the LFM diet had a distinct microbiota profile showing enriched taxa with a major saccharolytic metabolic function (e.g. *Bacteroides*, *Ruminococcaceae*, *F. prausnitzii*). No difference in  $\alpha$ -diversity (number of operational taxonomic units, *i.e.*, number of species) has been found after a one-week LFM diet. In a subsequent editorial,<sup>94</sup> the authors hypothesize that a larger effect size could have been found with a longer trial comparing the LFM and the TACD.

A recent study in adults with IBS confirmed that pre-treatment levels of selected gut microbial DNA markers (higher levels of *Bacteroides fragilis*, *Acinetobacter*, *Ruminiclostridium*, *Streptococcus*, and *Eubacterium*) were associated with higher probability to respond to FODMAP restriction.<sup>95</sup>

Two recent reviews<sup>38,96</sup> highlighted the limited data available in children,<sup>90,97</sup> and the need of larger, high quality studies to test the effectiveness of the LFM diet.

A recent pediatric single-blind, open-label, interventional proof-of-concept study<sup>98</sup> assessed the efficacy of an innovative, alternative approach. In this study, 18 exclusively breastfeeding healthy full-term infants aged 2–17 weeks who met criteria for infantile colic and their mothers were recruited for a dietary intervention trial. The infant's mothers were delivered a seven-day LFM diet and completed the Baby Day Diary on days five through seven to assess clinical study outcomes, and used a stopwatch to measure duration of sleep, feeding, crying, fussiness, and awake and content times. FODMAP content of breast milk and infant fecal samples for pH were analyzed at baseline and at the end of the dietary intervention. Crying duration decreased by 52 min compared to baseline [142 min] by the end of the dietary trial. Significant reductions in duration of fussiness and in number of episodes of crying were also reported. The analysis of breast milk lactose content was found to be stable throughout the intervention. Stool pH of infants was unchanged from baseline. Despite the lack of evidence, many breastfeeding mothers tend to practice a dietary change as a common strategy to relieve their infant's colic symptoms,<sup>99–102</sup> in some cases avoiding gas-producing foods (e.g., onions, garlic, cabbage, or legumes/pulses).<sup>101,102</sup>

Restricted diets, such as the LFM diet, need to be managed and supervised appropriately in both breastfeeding mothers and growing children, and in consultation with a specialized dietitian, as they can lead to a compromised nutritional adequacy and also to the development of poor eating behaviors and food fears.

**Table 2** Characteristics of the fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) pediatric studies included in the review.

Study	Methodology	Participants	Intervention	Duration of diet	Outcome measures and instruments	Key results
Chumpitazi et al., 2014 <sup>93</sup>	Open-label prospective study	Children aged 7–17 years ( <i>n</i> = 8) with IBS	Low FODMAP diet	7 days	Frequency of pain episodes; Instruments: Stool and Pain Diaries	Significantly ( <i>p</i> < 0.05) reduction in pain frequency, pain severity, and pain-related interference with activities. > 50% decrease in abdominal pain frequency was obtained with the LFD in four children (50%) identified as responder
Chumpitazi et al., 2015 <sup>90</sup>	Randomized, double-blind, cross-over study, with wash-out period	Children aged 7–17 years ( <i>n</i> = 33) with IBS	Low FODMAP vs. TACD diet	2 days	Children pain episodes frequency; Instruments: Pain and Stool Diary	16 children were initially treated with the low FODMAP diet while 17 began with the TACD; children on low FODMAP reported a decrease in daily abdominal pain episodes vs. children on following TACD [ $1.1 \pm 0.2$ (SEM) vs. $1.7 \pm 0.4$ pain episodes per day, respectively; <i>p</i> < 0.05].
Chumpitazi et al., 2018 <sup>108</sup>	Double-blind placebo-controlled (maltodextrin) cross-over trial with wash-out	Children with mean age $12.4 \pm 2.2$ years ( <i>n</i> = 23) and IBS	Fructans or maltodextrin (0.5 g/kg; maximum, 19 g).	3 days	Children pain episodes frequency; Instruments: Pain and Stool and Food Diaries	The fructan-containing diet was associated with significantly more severe bloating and flatulence and more mean episodes of abdominal pain/day ( $3.4 - 2.6$ ) compared to the maltodextrin-containing diet ( $2.4 - 1.7$ ) ( <i>p</i> < 0.01). More frequent abdominal pain while on the fructan-containing diet has been reported by 18 children (78.2%) and 12 (52.2%) qualified as fructan sensitive (defined as an increase of $\geq 30\%$ abdominal pain frequency following fructan ingestion); Sorbitol malabsorption has been diagnosed in 109/146 (75%) children; 27/31 (87%) had an improvement on a sorbitol-restricted diet.
Däbritz et al., 2014 <sup>124</sup>	Retrospective study	Children aged 3–18 years with RAP ( <i>n</i> = 206)	Lactose, fructose and/or sorbitol restricted diet	longer than 12 months in 55 patients [47%]	Improvement of symptoms; Instruments: follow-up questionnaire	55/142 (39%) children had fructose malabsorption. The number of children who specifically responded to a fructose-restricted diet is unclear, due to several patients in this cohort having multiple positive carbohydrate tests
Dearlove et al., 1983 <sup>109</sup>	Prospective study	Children aged >3 years with RAP ( <i>n</i> = 39)	Lactose restricted diet	2 weeks	Improvement of symptoms; Instruments: not specified	One-third of the children reported benefit from the lactose free diet, but no correlation was found with results of the lactose tolerance test, breath hydrogen estimation, or response to lactose challenges
Escobar et al., 2014 <sup>131</sup>	Retrospective study	Children aged 2–19 years with RAP ( <i>n</i> = 222)	Low-fructose diet	2 months (not clearly specify)	Improvement of symptoms; Instruments: Pain scale score	93/121 patients (76.9%) with BTH positive reported resolution of symptoms on a low-fructose diet ( <i>p</i> < 0.0001) compared to 55/101 patients (54.4%) with negative BHT for fructose ( <i>p</i> = 0.37).

Table 2 (Continued)

Study	Methodology	Participants	Intervention	Duration of diet	Outcome measures and instruments	Key results
Gijssbers et al., 2012 <sup>122</sup>	Prospective study with DBPC test of provocation	Children aged 4–16 years with RAP ( <i>n</i> = 220)	Low-lactose and/or fructose diet	3 days of provocation test	Resolution of abdominal pain with elimination, recurrence with provocation and disappearance with re-elimination; Instruments: not specified	Pain resolved upon elimination in 24/38 patients with lactose malabsorption, and in 32/49 with fructose malabsorption. A positive open provocation with lactose and fructose has been reported in 7/23 and 13/31 patients. DBPC provocation test done in 6/7 and 8/13 patients was negative in all, but a few children continued to report abdominal symptoms upon intake of milk or fructose.
Gomara et al., 2008 <sup>128</sup>	Prospective study	Children aged 7–17 years ( <i>n</i> = 32) FGIDs	Low-fructose and low-sorbitol diet	2 weeks	Improvement in their GI symptoms; Instruments: not specified	9 of 11 patients (81%) with positive fructose breath test results, reported almost immediate improvement in GI symptoms but a significant reduction only for abdominal pain and bloating ( <i>p</i> < 0.05)
Gremse et al., 2003 <sup>111</sup>	Randomized, double-blind, cross-over study	Children aged 3–17 years with RAP ( <i>n</i> = 30)	Lactose-hydrolyzed or lactose-containing milk	14 days	Improvement in their GI symptoms; Instruments: Daily diaries	A significant increase in abdominal pain was experienced by study participants during the lactose ingestion period when compared to the lactose-free period (total scores 7.5 + 2.7 vs. 4.1 + 1.4, <i>p</i> = 0.021)
Hammer et al., 2018 <sup>130</sup>	Prospective trial	Children with RAP, with history suggestive of a possible association of symptoms with fructose ingestion ( <i>n</i> = 82)	Fructose breath testing using: 1 g/kg body weight up to maximum of 25 g	–	Severity of clinical symptoms. Instruments: symptom questionnaire	A total of 33 children (40%) had malabsorption; fructose ingestion induced symptoms in 31 (38%), but only 15 (46%) with malabsorption were symptomatic; fructose malabsorption did not significantly correlate with fructose-induced symptoms; clinical symptoms correlated only with symptoms experienced during the breath test ( <i>p</i> < 0.001, <i>r</i> <sup>2</sup> = 0.21) but not with malabsorption (NS)
Iacovou et al., 2018 <sup>98</sup>	Single-blind, open-label, interventional study.	Exclusively breastfeeding mothers and their infants aged 2–17 weeks who met the Wessel Criteria for infantile colic ( <i>n</i> = 18)	Maternal low FODMAP diet	7 days	Infant crying-fussing durations (minutes), Instruments: Baby Day Diary	Infant crying-fussing durations fell by 73 [301–223] min ( <i>n</i> = 13; <i>p</i> = 0.007), as well as crying episodes ( <i>p</i> = 0.01) and fussing durations ( <i>p</i> = 0.011). “Much more content” babies were reported at end of study by their mothers



(Continued)

Study	Methodology	Participants	Intervention	Duration of diet	Outcome measures and instruments	Key results
Lebenthal et al., 1981 <sup>110</sup>	Prospective study	Children aged 6–14 years ( <i>n</i> = 69) RAP	Low-lactose diet	12 months	Improvement in RAP; Instruments: Symptoms Diary	Symptoms of RAP resolved in 40% lactose malabsorbers, in 38.4% lactose absorbers after 12 months of elimination diet and in 41.7% lactose absorbers following a regular diet.
Wintermeyer et al., 2012 <sup>129</sup>	Prospective study	Children aged 3–14 years ( <i>n</i> = 75) with RAP	Low-fructose and low-sorbitol diet	4 weeks	Improvement of frequency and intensity of abdominal pain; Instruments: nonstandard questionnaire	A median reduction of weekly pain frequency from a mean of 3.64 + 1.6 before diet to a mean of 1.46 + 1.4 ( <i>p</i> < 0.001) under fructose restriction was reported. The median intensity of pain decreased from 6 (mean 5.83 + 2.0) before intervention to 3 (mean 3.4 + 2.5; <i>p</i> < 0.001) on diet. A significant improvement of daily stool frequency, nausea, sleep problems, missed school days was also reported on diet
Wirth et al., 2014 <sup>97</sup>	Prospective, blinded randomized interventional trial	103 children with RAP: 51 restricted diet (group A), 52 standard diet (group B)	Fructose-restricted diet vs. standard diet	2 weeks	1. Pain intensity (measured by questionnaire) 2. Pain frequency (as above) 3. ‘‘Secondary symptoms score’’ (SSS) created from 8 parameters (nausea, vomiting, fatigue, sleep disturbance, headache, dizziness, anorexia, and use of pain relievers).	There was a significant decrease on pain score (from a median 5.5 to 4) in group A and no significant changes in group B (5.3–5) two weeks after intervention. Frequency of abdominal pain decreased in both groups but without significant difference, while SSS improved only in group A from median 6 to 3.5.

IBS, irritable bowel syndrome; RAP, recurrent abdominal pain; TACD, typical American childhood diet; LFD, low FODMAP diet; BHT, breath hydrogen test; DBPC, double blind placebo controlled.

### Fructans-related studies in children with FAPDs

Fructans are FODMAPs commonly present in the usual diet of adults and children.<sup>103</sup> Fructans are rich in fructosyl-fructose linkages that reach intact the colon intact, as they cannot be hydrolyzed by human enzymes.<sup>103–105</sup> These oligosaccharides undergo colonic fermentation, increasing gas production and subsequent luminal distension, which can exacerbate symptoms in individuals with IBS.<sup>42,106</sup> However, limiting fructans may reduce healthy foods (*i.e.*, fibers) and *Bifidobacteria*.<sup>104,107</sup>

In a recent double-blind, randomized, placebo-controlled crossover trial,<sup>108</sup> 23 children with IBS completed a one-week baseline abdominal pain and stool diaries and three-day food diaries. Depression, anxiety, and somatization scores were measured through validated questionnaires. Children were randomly assigned to receive meals containing either fructans or maltodextrin (0.5 g/kg; maximum, 19 g) for 72 h followed by a washout period of at least ten days.

Breath hydrogen and methane production were tested at baseline and during each study period. Fructan-sensitive and fructan-insensitive subjects were similar in baseline symptoms and diet, psychosocial evaluation, IBS subtype, and gas production. There were a significantly higher number of daily abdominal pain episodes, more severe bloating, and flatulence during the fructan-containing diet compared to the maltodextrin-containing diet. Hydrogen (but not methane) production was significantly higher during the fructan period).

### Lactose-related studies in children with FAPDs

Three RCT on a restricted lactose diet have been completed<sup>109–111</sup> in children with FAPDs<sup>112</sup> as well as a larger number of observational or uncontrolled trials.<sup>113–124</sup> Most of the older studies were conducted using old terminology of recurrent abdominal pain (RAP). Two out of the three RCT trials on lactose-free diet that were conducted in children with RAP<sup>109,110</sup> were evaluated by a Cochrane Review,<sup>125</sup> and included in a systematic review by Rutten et al.<sup>126</sup>

Lebenthal et al.<sup>110</sup> studied the effect of lactose intolerance in RAP through an uncontrolled treatment and a randomized controlled challenge. Thirty-eight of 69 children with lactose intolerance received six weeks of either lactose-containing or lactose-free infant formula. Lactose intake increased symptoms in 48% of the lactose malabsorbers and in 24% of the lactose absorbers. Forty of the 69 children continued with lactose free diet for 12-months. After 12 months, improvement of abdominal pain was similar in both groups regardless if they were lactose absorbers or malabsorbers (40% vs. 38%).

In another double blind, single crossover design trial conducted in 39 children with RAP,<sup>109</sup> children were instructed to continue with their usual diet for the first two weeks, while during the third and fourth weeks they received a lactose-free diet, and during the fifth and sixth weeks the children randomly received either lactose (2 g/kg) or a similarly flavored placebo. One-third of the children were reported to have benefitted from the lactose-free diet, but there was no correlation between the improvement and the

results of the lactose tolerance blood test, breath hydrogen test, or clinical response to lactose challenge.

In 2003, Gremse et al.<sup>111</sup> conducted a randomized, double-blinded, cross-over study. Thirty children, aged 3–17 years, affected by RAP and lactose maldigestion defined by >10-ppm increase in lactose breath hydrogen test received either lactose-hydrolyzed or lactose-containing milk for two weeks. Abdominal pain, bloating, flatulence, and diarrhea scores were similar in subjects who had >10-ppm or >20-ppm increase in breath hydrogen testing after ingesting lactose. Due to the conflicting results of the above studies, further prospective RCTs are necessary to clarify the efficacy of a lactose-restricted diet in children with AP-FGIDs who have lactose malabsorption,<sup>93</sup> whereas, according to a recent systematic review<sup>38</sup> the current evidence in the literature does not encourage the use of a lactose-restricted diet in all children with IBS. Data in adult studies are also inconclusive, and it is still unclear if the lactose malabsorption is part of the IBS symptoms, or if the two conditions may simply coexist in some patients.<sup>38</sup>

### Fructose-related studies in children with FAPDs

Fructose is a monosaccharide, of which American children consume a mean of 54.7 g/day (accounting for approximately 10% of their daily caloric intake).<sup>127</sup> Fructose is dependent on the glucose transporter 5 (GLUT5) and glucose transporter 2 (GLUT2) for passive absorption.<sup>112</sup> One prospective study on the effect of low lactose and/or fructose diet,<sup>116</sup> four prospective studies on the effect of a low fructose diet<sup>97,128,129</sup> or fructose ingestion,<sup>130</sup> and two retrospective studies<sup>124,131</sup> on the effect of a low-fructose diet have been conducted in children (Table 2).

In a prospective controlled trial,<sup>97</sup> 103 children with AP-FGIDs were randomized to either a fructose-restricted diet ( $n=51$ ) or a no dietary intervention group ( $n=52$ ) for two weeks. Lower abdominal pain intensity, but not frequency, was reported by those children on the fructose-restricted diet (irrespective of their fructose hydrogen breath test result). In a prospective observational trial,<sup>129</sup> 75 children with AP-FGIDs and positive fructose breath test on a restricted fructose diet showed an overall reduction on the abdominal pain frequency and pain severity.<sup>129</sup> Gomara et al.<sup>128</sup> performed fructose hydrogen breath testing using various doses of fructose, including 1 g, 15 g, and 45 g in 32 children with an AP-FGID. They found that 11 (34%) of the 32 children studied had fructose malabsorption either with the 15 g or 45 g doses. Following a two-week dietitian-recommended fructose-restricted diet, nine out of these 11 (82%) had a significant improvement.<sup>128</sup>

Recently, 82 children with functional abdominal pain disorders whose history was suggestive for a possible correlation with ingestion of fructose revealed that only 40% of them had malabsorption defined by increased breath hydrogen; just half of them with malabsorption were symptomatic. The authors suggested that visceral hypersensitivity, rather than malabsorption *per se*, may correlate with symptoms in some patients.<sup>130</sup> Escobar et al.<sup>131</sup> completed fructose breath testing using 1 g/kg (up to 25 g) in 222 children with AP-FGIDs and found that 121 out of 222 chil-

dren (55%) had fructose malabsorption, and 93 (77%) of them improved on a dietitian-recommended low-fructose diet.

In a retrospective study,<sup>124</sup> 55/142 (39%) children had fructose malabsorption identified by fructose hydrogen breath testing, but several also showed multiple positive carbohydrate tests, making the response to diet unclear. In another study<sup>122</sup> involving 220 children with RAP, some children still complained of abdominal symptoms when using milk or fructose-containing food despite a negative double-blind placebo-controlled provocation test with lactose or fructose (25% with milk and 48% with fructose, respectively).

Similarly to lactose,<sup>38,132</sup> an improvement in abdominal symptoms has been reported on fructose-restricted diet regardless of the presence or absence of fructose malabsorption.<sup>91,133,134</sup>

### Sorbitol-related studies in children with FAPDs

No prospective studies with only sorbitol restriction have been completed in children with AP-FGIDs,<sup>110</sup> while two prospective studies<sup>128,129</sup> evaluated a combination of low-fructose and low-sorbitol diet (Table 2).

A case report<sup>135</sup> described a 15-year-old girl with chronic abdominal pain, most likely due to sorbitol ingestion from sugar-free gum, which improved with elimination of the sorbitol source. In a retrospective study, Däbritz et al.<sup>124</sup> found that 109/146 (75%) children with RAP who underwent hydrogen breath testing had sorbitol malabsorption, and 27/31 (87%) who started a sorbitol-restricted diet reported symptom improvement.

### Discussion

A significant beneficial effect of an LFM diet on clinical symptoms has been reported by several studies in adults with IBS,<sup>37,97</sup> while in children there is currently very limited data, and only one small randomized double-blind study. The evidence to support a change in maternal diet for the treatment of infantile colic is also weak. Thus more research is needed before recommendations in children can be made.

Due to the complexity of designing LFM diets and the potential nutritional imbalances, guidance by professionals with expertise in dietary management is important, particularly in children to ensure nutritional adequacy and growth potential. It is currently difficult to predict which patients would benefit from LFM diets because of the lack of a specific biomarker and of a relation between breath tests and improvement of symptoms. When clinicians consider LFM diets, they should be aware of short-term and long-term limitations, including the impact on quality of life determined by multiple restrictions, the possible changes in gut microbiota, and the lack of knowledge of the relative efficacy in children.

Gradual reintroduction of FODMAPs into the diet after the elimination phase is currently recommended.<sup>82</sup> This approach allows a personalized diet based on individual tolerance and avoids over-restriction with potential nutritional imbalances. Supplementation with specific probiotics could also restore the gut microbiota altered by an LFM diet.<sup>83</sup>

Increasing the knowledge regarding FODMAP content, improving the foods labeling, and analysis are important<sup>70</sup>

for clinicians and dieticians to design a tailored LFM diet and for the patients to ease the dietary compliance.

Further research is still needed to identify the best way to reintroduce foods containing FODMAPs and to determine which food is responsible of symptoms for each patient.<sup>34</sup> Moreover, additional data on long-term adherence, effectiveness, and safety are also needed.

Current evidence does not support the use of a lactose-restricted diet in all children with IBS. Further work is needed to elucidate the role of exclusively restricting fructans and fructose for the treatment of pediatric FAPDs.

In conclusion, a low FODMAP diet is a promising dietary therapeutic intervention in adults with IBS, but the effectiveness of this approach in children with IBS and FAPDs remains unclear. Additional efforts are still needed to clarify which patients and which kind of FODMAP restriction would benefit to ensure nutritional adequacy, to facilitate recognition of FODMAP content, and to simplify the adherence to diet.

### Availability of data and material

Data sharing not applicable to this article, as no datasets were generated or analyzed during the current study.

### Conflicts of interest

There are no conflicts of interest related to this study. S. Salvatore has participated as consultant and/or speaker for Deca, IMS-Health, Danone, Nestlé, and Menarini; Nikhil Thapar has participated as an advisory board member and/or speaker for Nutricia and Danone. Yvan Vandenplas has participated as a clinical investigator, and/or advisory board member, and/or consultant, and/or speaker for Abbott Nutrition, Aspen, Biocodex, Danone, Nestle Health Science, Nestle Nutrition Institute, Nutricia, Mead Johnson Nutrition, Merck, Phacobel, Rontis, United Pharmaceuticals, Wyeth, and Yakult. Annamaria Staiano has participated as a clinical investigator, and/or advisory board member, and/or consultant, and/or speaker for D.M.G., Valeas, Angelini, Miltè, Danone, Nestlé, Sucampo, and Menarini. Miguel Saps has served as a Scientific Consultant for Forest, Quintiles, Ardeylx, IM HealthScience, QOL Medical, and Sucampo. All the above manufacturers and companies have had no input or involvement in any aspect of this study. The other authors have no conflicts of interest to disclose.

### Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at [doi:10.1016/j.jpeds.2019.03.004](https://doi.org/10.1016/j.jpeds.2019.03.004).

### References

1. Staudacher HM, Kurien M, Whelan K. Nutritional implications of dietary interventions for managing gastrointestinal disorders. *Curr Opin Gastroenterol.* 2018;34:105–11.
2. Drossman DA. The functional gastrointestinal disorders and the Rome III process. *Gastroenterology.* 2006;130:1377–90.

3. Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV. *Gastroenterology*. 2016;150:1262–79.
4. Benninga MA, Faure C, Hyman PE, St James Roberts I, Schechter NL, Nurko S. Childhood functional gastrointestinal disorders: neonate/toddler. *Gastroenterology*. 2016;150:1443–55.
5. Hyams JS, Di Lorenzo C, Saps M, Shulman RJ, Staiano A, van Tilburg M. Functional disorders: children and adolescents. *Gastroenterology*. 2016;150:1456–68.
6. Tarsitano F, Castelluzzo MA, Concolino D, Pensabene L. Functional abdominal pain. *Curr Pediatr Rep*. 2018;6:67–78.
7. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. *Clin Epidemiol*. 2014;6:71–80.
8. Boronat AC, Ferreira-Maia AP, Matijasevich A, Wang YP. Epidemiology of functional gastrointestinal disorders in children and adolescents: a systematic review. *World J Gastroenterol*. 2017;23:3915–92.
9. Giannetti E, de'Angelis G, Turco R, Campanozzi A, Pensabene L, Salvatore S, et al. Subtypes of irritable bowel syndrome in children: prevalence at diagnosis and at follow-up. *J Pediatr*. 2014;164:1099–110.
10. Bueno L, Fioramonti J. Visceral perception: inflammatory and non-inflammatory mediators. *Gut*. 2002;51:i19–23.
11. Accarino AM, Azpiroz F, Malagelada JR. Selective dysfunction of mechanosensitive intestinal afferents in irritable bowel syndrome. *Gastroenterology*. 1995;108:636–43.
12. Kellow JE, Eckersley GM, Jones M. Enteric and central contributions to intestinal dysmotility in irritable bowel syndrome. *Dig Dis Sci*. 1992;37:168–74.
13. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. *JAMA*. 2004;292:852–8.
14. Barbara G, De Giorgio R, Stanghellini V, Cremon C, Corinaldesi R. A role for inflammation in irritable bowel syndrome? *Gut*. 2002;51:i41–4.
15. Pensabene L, Talarico V, Concolino D, Ciliberto D, Campanozzi A, Gentile T, et al. Post-infectious functional gastrointestinal disorders in children: a multicenter prospective study. *J Pediatr*. 2015;166:903–7.
16. Saps M, Pensabene L, Turco R, Staiano A, Cupuro D, Di Lorenzo C. Rotavirus gastroenteritis: precursor of functional gastrointestinal disorders? *J Pediatr Gastroenterol Nutr*. 2009;49:580–3.
17. Saps M, Pensabene L, Di Martino L, Staiano A, Weschler J, Zheng X, et al. Post-infectious functional gastrointestinal disorders in children. *J Pediatr*. 2008;152:812–6.
18. Drossman DA, McKee DC, Sandler RS, Mitchell CM, Cramer EM, Lowman BC, et al. Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and non patients with irritable bowel syndrome. *Gastroenterology*. 1988;95:701–8.
19. Bonilla S, Saps M. Early life events predispose the onset of childhood functional gastrointestinal disorders. *Rev Gastroenterol Mex*. 2013;78:82–91.
20. Turco R, Miele E, Russo M, Mastroianni R, Lavorgna A, Paludetto R, et al. Early-life factors associated with pediatric functional constipation. *J Pediatr Gastroenterol Nutr*. 2014;58:307–12.
21. Saps M, Lu P, Bonilla S. Cow's-milk allergy is a risk factor for the development of FGIDs in children. *J Pediatr Gastroenterol Nutr*. 2011;52:166–9.
22. Pensabene L, Salvatore S, D'Auria E, Parisi F, Concolino D, Borrelli O, et al. Cow's milk protein allergy in infancy: a risk factor for functional gastrointestinal disorders in children? *Nutrients*. 2018;10:1716.
23. Tougas G. The autonomic nervous system in functional bowel disorders. *Can J Gastroenterol*. 1999;13:15a–7a.
24. Mayer EA, Tillisch K. The brain-gut axis in abdominal pain syndromes. *Annu Rev Med*. 2011;62:381–96.
25. Buonavolontà R, Coccorullo P, Turco R, Boccia G, Greco L, Staiano A. Familial aggregation in children affected by functional gastrointestinal disorders. *J Pediatr Gastroenterol Nutr*. 2010;50:500–5.
26. Henstrom M, Diekmann L, Bonfiglio F, Hadizadeh F, Kuech EM, von Köckritz-Blickwede M, et al. Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome. *Gut*. 2018;67:263–70.
27. Llanos-Chea A, Fasano A. Gluten and functional abdominal pain disorders. *Nutrients*. 2018;10:1491.
28. Mayer EA, Savidge T, Shulman RJ. Brain-gut microbiome interactions and functional bowel disorders. *Gastroenterology*. 2014;146:1500–12.
29. Eswaran S, Tack J, Chey WD. Food: the forgotten factor in the irritable bowel syndrome. *Gastroenterol Clin North Am*. 2011;40:141–62.
30. Hayes P, Corish C, O'Mahony E, Quigley EM. A dietary survey of patients with irritable bowel syndrome. *J Hum Nutr Diet*. 2014;27:36–47.
31. Bohn L, Storsrud S, Tornblom H, Bengtsson U, Simrén M. Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life. *Am J Gastroenterol*. 2013;108:634–41.
32. Simrén M, Abrahamsson H, Björnsson ES. Exaggerated sensory component of the gastrocolonic response in patients with IBS. *Gut*. 2001;48:20–7.
33. Salvioli B, Serra J, Azpiroz F, Malagelada JR. Impaired small bowel gas propulsion in patients with bloating during intestinal lipid infusion. *Am J Gastroenterol*. 2006;101:1853–7.
34. Dolan R, Chey WD, Eswaran D. The role of diet in the management of irritable bowel syndrome: a focus on FODMAPs. *Expert Rev Gastroenterol Hepatol*. 2018;12:607–15.
35. Spencer M, Chey WD, Eswaran S. Dietary renaissance in IBS: has food replaced medications as a primary treatment strategy? *Curr Treat Options Gastroenterol*. 2014;12:424–40.
36. Oświęcimska J, Szymłak A, Roczniak W, Girczys-Potędniok K, Kwiecień J. New insights into the pathogenesis and treatment of irritable bowel syndrome. *Adv Med Sci*. 2017;62:17–30.
37. Marsh A, Eslick EM, Eslick GD. Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis. *Eur J Nutr*. 2016;55:897–906.
38. Newlove-Delgado TV, Martin AE, Abbott RA, Bethel A, Thompson-Coon J, Whear R, et al. Dietary interventions for recurrent abdominal pain in childhood. *Cochrane Database Syst Rev*. 2017;3:CD010972.
39. Zannini E, Arendt EK. Low FODMAPs and Gluten-free foods for irritable bowel syndrome treatment: lights and shadows. *Food Res Int*. 2018;110:33–41.
40. Barrett JS, Geary RB, Muir JG, Irving PM, Rose R, Rosella O, et al. Dietary poorly absorbed, shortchain carbohydrates increase delivery of water and fermentable substrates to the proximal colon. *Aliment Pharmacol Ther*. 2010;31:874–82.
41. Ong DK, Mitchell SB, Barrett JS, Shepherd SJ, Irving PM, Biesiekierski JR, et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. *J Gastroenterol Hepatol*. 2010;25:1366–73.
42. Murray K, Wilkinson-Smith V, Hoad C, Costigan C, Cox E, Lam C, et al. Differential effects of FODMAPs (fermentable oligo-, di-, mono-saccharides and polyols) on small and large intestinal contents in healthy subjects shown by MRI. *Am J Gastroenterol*. 2014;109:110–9.
43. El-Salhy M, Gundersen D. Diet in irritable bowel syndrome. *Nutr J*. 2015:36.

44. Böhn L, Störsrud S, Liljebo T, Collin L, Lindfors P, Törnblom H, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. *Gastroenterology*. 2015;149:1399–407.
45. Staudacher HM, Whelan K, Irving PM, Lomer MC. Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. *J Hum Nutr Diet*. 2011;24:487–95.
46. Chatterjee S, Park S, Low K, Kong Y, Pimentel M. The degree of breath methane production in IBS correlates with the severity of constipation. *Am J Gastroenterol*. 2007;102:837–41.
47. Pimentel M, Mayer AG, Park S, Chow EJ, Hasan A, Kong Y. Methane production during lactulose breath test is associated with gastrointestinal disease presentation. *Dig Dis Sci*. 2003;48:86–92.
48. Nath A, Haktanirlar G, Varga Á, Molnár MA, Albert K, Galambos I, et al. Biological activities of lactose derived prebiotics and symbiotic with probiotics on gastrointestinal system. *Medicina (Kaunas)*. 2018;54:18.
49. Markowiak P, Śliżewska K. Effects of probiotics, prebiotics, and synbiotics on human health. *Nutrients*. 2017;9:1021.
50. Gibson PR, Shepherd SJ. Personal view: food for thought – western lifestyle and susceptibility to Crohn’s disease. The FODMAP hypothesis. *Aliment Pharmacol Ther*. 2005;21:1399–409.
51. Shepherd SJ, Gibson PR. Fructose malabsorption and symptoms of irritable bowel syndrome: guidelines for effective dietary management. *J Am Diet Assoc*. 2006;106:1631–9.
52. National Institute for Health and Care Excellence (NICE). Irritable bowel syndrome in adults; diagnosis and management of irritable bowel syndrome in primary care. London: NICE; 2015.
53. Gibson PR, Shepherd SJ. Food choice as a key management strategy for functional gastrointestinal symptoms. *Am J Gastroenterol*. 2012;107:657–66.
54. Khan MA, Nusrat A, Khan MI, Nawras A, Bielefeldt K. Low-FODMAP diet for irritable bowel syndrome: is it ready for prime time? *Dig Dis Sci*. 2015;60:1169–77.
55. Barrett JS. How to institute the low-FODMAP diet. *J Gastroenterol Hepatol*. 2017;32:8–10.
56. Varney J, Barrett J, Scarlata K, Catsos P, Gibson PR, Muir JG. FODMAPs: food composition, defining cutoff values and international application. *J Gastroenterol Hepatol*. 2017;32:53–61.
57. Monash University Low FODMAP Diet app; 2016. Available from: <http://www.med.monash.edu.au/cecs/gastro/fodmap/iphone-app.html> [cited 27.03.19].
58. Digestive Health Foundation. Available from: <http://www.CDHF.ca> [cited 27.03.19].
59. Magge S, Lembo A. Low-FODMAP diet for treatment of irritable bowel syndrome. *Gastroenterol Hepatol (NY)*. 2012;8:739–45.
60. Madsen JL, Linnet J, Rumessen JJ. Effect of non absorbed amounts of a fructose-sorbitol mixture on small intestinal transit in healthy volunteers. *Dig Dis Sci*. 2006;51:147–53.
61. McIntosh K, Reed DE, Schneider T, Dang F, Keshteli AH, De Palma G, et al. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. *Gut*. 2017;66:1241–51.
62. Hustoft TN, Hausken T, Ystad SO, Valeur J, Brokstad K, Hatlebakk JG, et al. Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome. *Neurogastroenterol Motil*. 2017;29:4.
63. Zhou SY, Gilliland M 3rd, Wu X, Leelasinjaroen P, Zhang G, Zhou H, et al. FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction. *J Clin Invest*. 2018;128:267–80.
64. Boradyn KM, Przybyłowicz KE. Low FODMAP diet: a potential treatment of functional abdominal pain in children. *Perspect Public Health*. 2017;137:314–5.
65. Halmos EP. A low FODMAP diet in patients with Crohn’s disease. *J Gastroenterol Hepatol*. 2016;31 Suppl. 1:5–14.
66. Barrett JS, Gibson PR. Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and nonallergic food intolerance: FODMAPs or food chemicals? *Therap Adv Gastroenterol*. 2012;5:261–8.
67. Whelan K, Martin LD, Staudacher HM, Lomer MC. The low FODMAP diet in the management of irritable bowel syndrome: an evidence based review of FODMAP restriction, reintroduction and personalisation in clinical practice. *J Hum Nutr Diet*. 2018;31:239–55.
68. Chey WD. Food: the main course to wellness and illness in patients with irritable bowel syndrome. *Am J Gastroenterol*. 2016;111:366–71.
69. Tuck C, Barrett J. Re-challenging FODMAPs: the low FODMAP diet phase two. *J Gastroenterol Hepatol*. 2017;32 Suppl. 1:5–11.
70. Chumpitazi BP, Lim J, McMeans AR, Shulman RJ, Hamaker BR. Evaluation of FODMAP carbohydrates content in selected foods in the United States. *J Pediatr*. 2018;199:252–5.
71. Muir JG, Rose R, Rosella O, Liels K, Barrett JS, Shepherd SJ, et al. Measurement of short-chain carbohydrates in common Australian vegetables and fruits by high-performance liquid chromatography (HPLC). *J Agric Food Chem*. 2009;57:554–65.
72. McMeans AR, King KL, Chumpitazi BP. Low FODMAP dietary food lists are often discordant. *Am J Gastroenterol*. 2017;112:655–6.
73. Biesiekierski JR, Rosella O, Rose R, Liels K, Barrett JS, Shepherd SJ, et al. Quantification of fructans, galactooligosaccharides and other shortchain carbohydrates in processed grains and cereals. *J Hum Nutr Diet*. 2011;24:154–76.
74. Muir JG, Gibson PR. The low FODMAP diet for treatment of irritable bowel syndrome and other gastrointestinal disorders. *Gastroenterol Hepatol (NY)*. 2013;9:450–2.
75. Gibson PR, Burgell RE. Easing concerns about the low FODMAP diet in patients with irritable bowel syndrome. *Gastroenterology*. 2017;153:886–7.
76. Does a low FODMAP diet help IBS? *Drugs Ther Bull*. 2015;51:91–6.
77. Krogsgaard LR, Lyngesen M, Bytzer P. Systematic review: quality of trials on the symptomatic effects of the low FODMAP diet for irritable bowel syndrome. *Aliment Pharmacol Ther*. 2017;45:1506–13.
78. Yao CK, Gibson PR, Shepherd SJ. Design of clinical trials evaluating dietary interventions in patients with functional gastrointestinal disorders. *Am J Gastroenterol*. 2013;108:748–58.
79. Staudacher HM. Nutritional, microbiological and psychosocial implications of the low FODMAP diet. *J Gastroenterol Hepatol*. 2017;32 Suppl. 1:16–9.
80. Larsen T, Hausken T, Otteraaen YS, Hovdenak N, Mueller B, Lied GA. Does the low FODMAP diet improve symptoms of radiation-induced enteropathy? A pilot study. *Scand J Gastroenterol*. 2017;7:1–8.
81. O’Keeffe M, Jansen C, Martin L, Williams M, Seamark L, Staudacher HM, et al. Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome. *Neurogastroenterol Motil*. 2018;30:e13154.
82. Harvie RM, Chisholm AW, Bisanz JE, Burton JP, Herbison P, Schultz K, et al. Long-term irritable bowel syndrome symptom control with reintroduction of selected FODMAPs. *World J Gastroenterol*. 2017;23:4632–43.
83. Staudacher HM, Lomer MC, Farquharson FM, Louis P, Fava F, Franciosi E, et al. A diet low in FODMAPs reduces symptoms in patients with irritable bowel syndrome and a probiotic restores

- Bifidobacterium* species: a randomized controlled trial. *Gastroenterology*. 2017;153:936–47.
84. de Roest RH, Dobbs BR, Chapman BA, Batman B, O'Brien LA, Leeper JA, et al. The low FODMAP diet improves gastrointestinal symptoms in patients with irritable bowel syndrome: a prospective study. *Int J Clin Pract*. 2013;67:895–903.
  85. Staudacher H, Ross FS, Briscoe ZM, Irving PM, Whelan K, Lomer MC. Advice from a dietitian regarding the low FODMAP diet broadly maintains nutrient intake and does not alter fibre intake. *Gut*. 2015;64:A143–4.
  86. Farida JP, Shah ED, Ball S, Chey WD, Eswaran SL. Micronutrient intake changes with the low FODMAP and mNICE diets. *Amer J Gastroenterol*. 2017;112:S247.
  87. Eswaran SL, Chey WD, Han-Markey T, Ball S, Jackson K. A randomized controlled trial comparing the low FODMAP diet vs. modified nice guidelines in US adults with IBS-D. *Am J Gastroenterol*. 2016;111:1824–32.
  88. Catassi G, Lionetti E, Gatti S, Catassi C. The Low FODMAP Diet: many question marks for a catchy acronym. *Nutrients*. 2017;16:E292.
  89. Brewer MS. Natural antioxidants: sources, compounds, mechanisms of action, and potential applications. *Compr Rev Food Sci Food Saf*. 2011;10:221–47.
  90. Chumpitazi BP, Cope JL, Hollister EB, Tsai CM, McMeans AR, Luna RA, et al. Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with irritable bowel syndrome. *Aliment Pharmacol Ther*. 2015;42:418–27.
  91. Halmos EP, Christophersen CT, Bird AR, Shepherd SJ, Gibson PR, Muir JG. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. *Gut*. 2015;64:93–100.
  92. Lis DM, Stellingwerff T, Kitic CC, Fell JM, Ahuja KD. Low Fodmap: a preliminary strategy to reduce gastrointestinal distress in athletes. *Med Sci Sports Exerc*. 2018;50:116–23.
  93. Chumpitazi BP, Hollister EB, Oezgüen N, Tsai CM, McMeans AR, Luna RA, et al. Gut microbiota influences low fermentable substrate diet efficacy in children with irritable bowel syndrome. *Gut Microb*. 2014;5:165–75.
  94. Chumpitazi BP, Shulman RJ. Editorial: predicting response to a low FODMAP diet in children – authors' reply. *Aliment Pharmacol Ther*. 2015;42:776.
  95. Valeur J, Småstuen MC, Knudsen T, Lied GA, Røseth AG. Exploring gut microbiota composition as an indicator of clinical response to dietary FODMAP restriction in patients with irritable bowel syndrome. *Dig Dis Sci*. 2018;63:429–36.
  96. Turco R, Salvatore S, Miele E, Romano C, Marseglia GL, Staiano A. Does a low FODMAPs diet reduce symptoms of functional abdominal pain disorders? A systematic review in adult and paediatric population, on behalf of Italian Society of Pediatrics. *Ital J Pediatr*. 2018;44:53.
  97. Wirth S, Klodt C, Wintermeyer P, Berrang J, Hensel K, Langer T, et al. Positive or negative fructose breath test results do not predict response to fructose restricted diet in children with recurrent abdominal pain: results from a prospective randomized trial. *Klin Padiatr*. 2014;226:268–73.
  98. Iacovou M, Mulcahy EC, Truby H, Barrett JS, Gibson PR, Muir JG. Reducing the maternal dietary intake of indigestible and slowly absorbed short-chain carbohydrates is associated with improved infantile colic: a proof-of-concept study. *J Hum Nutr Diet*. 2018;31:256–65.
  99. Iacovou M. Adapting the low FODMAP diet to special populations: infants and children. *J Gastroenterol Hepatol*. 2017;32:43–5.
  100. Iacovou M, Ralston RA, Muir J, Walker KZ, Truby H. Dietary management of infantile colic: a systematic review. *Matern Child Health J*. 2012;16:1319–31.
  101. Abdallah E, Elneim A. Dietary habits during the postpartum period among a sample of lactating women in Sudan. *J Nurs Health Sci*. 2014;3:1–6.
  102. Alouane L, Ghrissi A, Benkhaled I. Dietary habits of postpartum mothers during breastfeeding. *Ann Nutr Metab*. 2013;63:412.
  103. Moshfegh AJ, Friday JE, Goldman JP, Ahuja JK. Presence of inulin and oligofructose in the diets of Americans. *J Nutr*. 1999;129:1407S–11S.
  104. Roberfroid MB. Inulin-type fructans: functional food ingredients. *J Nutr*. 2007;137:2493S–502S.
  105. Niness KR. Inulin and oligofructose: what are they? *J Nutr*. 1999;129:1402S–6S.
  106. Shepherd SJ, Parker FC, Muir JG, Gibson PR. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. *Clin Gastroenterol Hepatol*. 2008;6:765–71.
  107. Carabin IG, Flamm WG. Evaluation of safety of inulin and oligofructose as dietary fiber. *Regul Toxicol Pharmacol*. 1999;30:268–82.
  108. Chumpitazi BP, McMeans AR, Vaughan A, Ali A, Orlando S, Elsaadi A, et al. Fructans exacerbate symptoms in a subset of children with irritable bowel syndrome. *Gastroenterol Hepatol*. 2018;16:219–25.
  109. Dearlove J, Dearlove B, Pearl K, Primavesi R. Dietary lactose and the child with abdominal pain. *Br Med J*. 1983;286:1936102.
  110. Lebenthal E, Rossi TM, Nord KS, Branski D. Recurrent abdominal pain and lactose absorption in children. *Pediatrics*. 1981;67:828–32.
  111. Gremse DA, Greer AS, Vacik J, DiPalma JA. Abdominal pain associated with lactose ingestion in children with lactose intolerance. *Clin Pediatr*. 2003;42:341–5.
  112. Chumpitazi BP, Shulman RJ. Dietary carbohydrates and childhood functional abdominal pain. *Ann Nutr Metab*. 2016;68 Suppl. 1:8–17.
  113. Liebman WM. Recurrent abdominal pain in children: lactose and sucrose intolerance, a prospective study. *Pediatrics*. 1979;64:43–5.
  114. Barr RG, Levine MD, Watkins JB. Recurrent abdominal pain of childhood due to lactose intolerance. *N Engl J Med*. 1979;300:1449–52.
  115. Christensen MF. Recurrent abdominal pain and dietary fiber. *Am J Dis Child*. 1986;140:738–9.
  116. Blumenthal I, Kelleher J, Littlewood JM. Recurrent abdominal pain and lactose intolerance in childhood. *Br Med J (Clin Res Ed)*. 1981;282:2013–4.
  117. Wald A, Chandra R, Fisher SE, Gartner JC, Zitelli B. Lactose malabsorption in recurrent abdominal pain of childhood. *J Pediatr*. 1982;100:65–8.
  118. Bhan MK, Arora NK, Ghai OP, Dhamija NK, Nayyar S, Fotedar A. Lactose and milk intolerance in recurrent abdominal pain of childhood. *Indian J Pediatr*. 1982;49:199–202.
  119. Webster RB, DiPalma JA, Gremse DA. Lactose maldigestion and recurrent abdominal pain in children. *Dig Dis Sci*. 1995;40:1506–10.
  120. Ceriani R, Zuccato E, Fontana M, Zuin G, Ferrari L, Principi N, et al. Lactose malabsorption and recurrent abdominal pain in Italian children. *J Pediatr Gastroenterol Nutr*. 1988;7:852–7.
  121. Gremse DA, Nguyenduc GH, Sacks AI, DiPalma JA. Irritable bowel syndrome and lactose maldigestion in recurrent abdominal pain in childhood. *South Med J*. 1999;92:778–81.
  122. Gijsbers CF, Kneepkens CM, Buller HA. Lactose and fructose malabsorption in children with recurrent abdominal pain: results of double-blinded testing. *Acta Paediatr*. 2012;101:e411–5.
  123. Ockeloen LE, Deckers-Kocken JM. Short and long-term effects of a lactose-restricted diet and probiotics in children with

- chronic abdominal pain: a retrospective study. *Complement Ther Clin Pract.* 2012;18:81–4.
124. Däbritz J, Mühlbauer M, Domagk D, Voos N, Henneböhl G, Siemer ML, et al. Significance of hydrogen breath tests in children with suspected carbohydrate malabsorption. *BMC Pediatr.* 2014;14:59.
  125. Huertas-Ceballos A, Logan S, Bennett C, Macarthur C. Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. *Cochrane Database Syst Rev.* 2008;23:CD003019.
  126. Rutten JM, Korterink JJ, Venmans LM, Benninga MA, Tabbers MM. Nonpharmacologic treatment of functional abdominal pain disorders: a systematic review. *Pediatrics.* 2015;135:522–35.
  127. Vos MB, Kimmons JE, Gillespie C, Welsh J, Blanck HM. Dietary fructose consumption among US children and adults: the Third National Health and Nutrition Examination Survey. *Medscape J Med.* 2008;10:160.
  128. Gomara RE, Halata MS, Newman LJ, Bostwick HE, Berezin SH, Cukaj L, et al. Fructose intolerance in children presenting with abdominal pain. *J Pediatr Gastroenterol Nutr.* 2008;47:303–8.
  129. Wintermeyer P, Baur M, Pilic D, Schmidt-Choudhury A, Zilbauer M, Wirth S. Fructose malabsorption in children with recurrent abdominal pain: positive effects of dietary treatment. *Klin Padiatr.* 2012;224:17–21.
  130. Hammer V, Hammer K, Memaran N, Huber WD, Hammer K, Hammer J. Relationship between abdominal symptoms and fructose ingestion in children with chronic abdominal pain. *Dig Dis Sci.* 2018;63:1270–9.
  131. Escobar MA Jr, Lustig D, Pflugeisen BM, Amoroso PJ, Sherif D, Saeed R, et al. Fructose intolerance/malabsorption and recurrent abdominal pain in children. *J Pediatr Gastroenterol Nutr.* 2014;58:498–501.
  132. Heyman MB. Lactose intolerance in infants, children, and adolescents. *Pediatrics.* 2006;118:1279–86.
  133. Youssef NN, Murphy TG, Langseder AL, Rosh JR. Quality of life for children with functional abdominal pain: a comparison study of patients' and parents' perceptions. *Pediatrics.* 2006;117:54–9.
  134. Berg LK, Fagerli E, Martinussen M, Myhre AO, Florholmen J, Goll R. Effect of fructose-reduced diet in patients with irritable bowel syndrome, and its correlation to a standard fructose breath test. *Scand J Gastroenterol.* 2013;48:936–43.
  135. Hyams JS. Chronic abdominal pain caused by sorbitol malabsorption. *J Pediatr.* 1982;100:772–3.